LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

95.39 -0.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

93.47

Max

95.99

Galvenie mērījumi
By Trading Economics
Ienākumi	19M 424M
Pārdošana	150M 1.4B
P/E Sektora vidējais	16.39 77.671
EPS	2.26
Peļņas marža	31.052
Darbinieki	2,617
EBITDA	-75M 506M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+5.1% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	808M 19B
Iepriekšējā atvēršanas cena	96.02
Iepriekšējā slēgšanas cena	95.39

Ziņu noskaņojums

By Acuity

40%

60%

135 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. dec. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025. g. 12. dec. 17:32 UTC

Iegādes, apvienošanās, pārņemšana

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025. g. 12. dec. 17:31 UTC

Iegādes, apvienošanās, pārņemšana

Orange to Buy the Stake for EU4.25B in Cash

2025. g. 12. dec. 17:24 UTC

Tirgus saruna

Argentina Predicts Record Wheat Crop -- Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 17:18 UTC

Tirgus saruna

Peļņas

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 12. dec. 16:47 UTC

Tirgus saruna

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

2025. g. 12. dec. 16:39 UTC

Tirgus saruna

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

2025. g. 12. dec. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 16:15 UTC

Peļņas

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

2025. g. 12. dec. 15:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 14:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

5.1% augšup

Prognoze 12 mēnešiem

Vidējais 101 USD 5.1%

Augstākais 125 USD

Zemākais 73 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

135 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation